China's Regulators Come Knocking Again at Pharma's Door

Last week, China's National Development and Economic Reform Commission (NDRC) announced that it was beginning an investigation around price collusion between domestic and foreign pharmaceutical manufacturers.  For those inside of China's pharmaceutical sector, the question is how to interpret the announcement.  This is not the first time China's regulators have used their varied powers to look at pricing practices across the country's healthcare economy.